EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq futures fall as oil prices jump, key earnings loom
- Brent hits five-month high as attacks on ships, Saudi sites fuel supply worries
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
- Cerebras Systems falls as TD Cowen cuts price target
- Nasdaq climbs as chip and AI-linked stocks bounce back
- 3M issues warrant to Amazon in $6B data center product deal
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 1, 2021 4:01 PM ESTWATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be... More



